Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Roberts

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African AmericansPatrick J Roberts, Kristan D Rollins, Angela D M Kashuba, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapyAnne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, et al.
Science Translational Medicine|April 28, 2017
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustionShenghui He, Patrick J Roberts, Jessica A Sorrentino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Predicting drug responsiveness in human cancers using genetically engineered miceJerry Usary, Wei Zhao, David Darr, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2021
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancerChao Li, Lowell Hart, Taofeek K Owonikoko, et al.
The Journal of Molecular Diagnostics : JMD|May 25, 2013
Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimensMatthew D Wilkerson, Jason M Schallheim, D Neil Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Nature|March 20, 2012
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseZhao Chen, Katherine Cheng, Zandra Walton, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 21, 2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African AmericansPatrick J Roberts, Kristan D Rollins, Angela D M Kashuba, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapyAnne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, et al.
Science Translational Medicine|April 28, 2017
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustionShenghui He, Patrick J Roberts, Jessica A Sorrentino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Predicting drug responsiveness in human cancers using genetically engineered miceJerry Usary, Wei Zhao, David Darr, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2021
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancerChao Li, Lowell Hart, Taofeek K Owonikoko, et al.
The Journal of Molecular Diagnostics : JMD|May 25, 2013
Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimensMatthew D Wilkerson, Jason M Schallheim, D Neil Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Nature|March 20, 2012
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseZhao Chen, Katherine Cheng, Zandra Walton, et al.
Cancer Discovery|November 5, 2017
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationJiehui Deng, Eric S Wang, Russell W Jenkins, et al.
Pageof 2